What is the total value of the Organon deal for Roivant?

Organon will pay aggregate consideration of up to approximately $1.2 billion, which includes a $175 million upfront payment, a $75 million milestone upon U.S. atopic dermatitis approval, and up to $950 million in sales milestones, plus tiered royalties on net sales.

When is the transaction expected to close?

The companies expect closing in the fourth quarter of 2024, subject to Hart-Scott-Rodino Antitrust Improvements Act review and other customary conditions.

How will the deal affect Organon's financial metrics?

Organon expects the transaction to be modestly dilutive to Adjusted EBITDA in 2025, turning accretive in 2026, and expects net leverage to be elevated above 4.0x. The company states the transaction is not expected to change its capital allocation priorities.

What does Roivant gain from the transaction?

According to Roivant's investor presentation, the deal generates meaningful additional capital, including about $500 million in upfront, near-term milestones and cash savings, and removes about $324 million of debt from Roivant's consolidated balance sheet. Roivant also retains a 30% royalty on VTAMA net sales above $1 billion, plus tiered royalties below that level, with royalties beginning in 2027.

What is the status of VTAMA's regulatory progress?

VTAMA cream is FDA-approved for plaque psoriasis in adults (May 2022). An sNDA for atopic dermatitis in adults and children two years and older is under FDA review, with a PDUFA action expected in the fourth quarter of calendar 2024.

ROIV 8-K: Regulation FD

01—Abstract

Summary

Summary of the 8-K filed September 18, 2024. Cited figures are marked; the original filing is the authoritative source.

On September 18, 2024, Roivant Sciences Ltd. (ROIV) and Organon & Co. (NYSE: OGN) announced a definitive Agreement and Plan of Merger under which Organon will acquire Dermavant Sciences Ltd., Roivant's majority-owned subsidiary that owns the rights to VTAMA (tapinarof) cream, 1%^a, globally excluding China and with Japan rights out-licensed.

Aggregate consideration is up to approximately $1.2 billion^b, consisting of a $175 million upfront payment, a $75 million milestone upon regulatory approval in atopic dermatitis (AD), and up to $950 million in commercial sales milestones, plus tiered royalties on net sales. Organon will also assume Dermavant liabilities with an approximate value of $286 million as of June 30, 2024. The filing states that the transaction is subject to Hart-Scott-Rodino review and other customary conditions, with closing expected in the fourth quarter of 2024.

Organon expects the deal to be modestly dilutive to Adjusted EBITDA in 2025 and accretive in 2026, with net leverage expected to be elevated above 4.0x. Roivant's investor presentation states that the deal removes all debt (about $324 million^c) from Roivant's consolidated balance sheet and includes a 30% royalty on net sales above $1 billion, in addition to tiered royalties below that level, with royalties beginning in 2027.

VTAMA is approved for plaque psoriasis in adults, and an sNDA for atopic dermatitis is under FDA review with a PDUFA action expected in the fourth quarter of 2024. The deal's value to investors depends heavily on this regulatory milestone and on future commercial sales, since most of the consideration is contingent.

02—Key points

Key Highlights

Organon to acquire Dermavant, which owns VTAMA (tapinarof) cream, 1%, for up to approximately $1.2 billion in aggregate consideration.
Upfront payment of $175 million at closing; $75 million milestone upon regulatory approval in atopic dermatitis; up to $950 million in commercial sales milestones.
Organon to assume Dermavant liabilities with an approximate value of $286 million as of June 30, 2024.
Roivant's investor presentation states the deal removes all debt (about $324 million) from its consolidated balance sheet and provides roughly $500 million in upfront, near-term milestones and cash savings.
Roivant's investor presentation notes it will receive 100% of payments to equity holders up to the liquidation preference of its preferred shares (currently $187.5 million) and holds 82% of Dermavant's equity on a fully-diluted basis.
Transaction expected to close in Q4 2024, subject to Hart-Scott-Rodino review and other customary conditions.
VTAMA's atopic dermatitis sNDA has a PDUFA action expected in Q4 2024, a key catalyst that would trigger a $75 million milestone.

03—Questions

Frequently Asked Questions

What is the total value of the Organon deal for Roivant?
Organon will pay aggregate consideration of up to approximately $1.2 billion, which includes a $175 million upfront payment, a $75 million milestone upon U.S. atopic dermatitis approval, and up to $950 million in sales milestones, plus tiered royalties on net sales.
When is the transaction expected to close?
The companies expect closing in the fourth quarter of 2024, subject to Hart-Scott-Rodino Antitrust Improvements Act review and other customary conditions.
How will the deal affect Organon's financial metrics?
Organon expects the transaction to be modestly dilutive to Adjusted EBITDA in 2025, turning accretive in 2026, and expects net leverage to be elevated above 4.0x. The company states the transaction is not expected to change its capital allocation priorities.
What does Roivant gain from the transaction?
According to Roivant's investor presentation, the deal generates meaningful additional capital, including about $500 million in upfront, near-term milestones and cash savings, and removes about $324 million of debt from Roivant's consolidated balance sheet. Roivant also retains a 30% royalty on VTAMA net sales above $1 billion, plus tiered royalties below that level, with royalties beginning in 2027.
What is the status of VTAMA's regulatory progress?
VTAMA cream is FDA-approved for plaque psoriasis in adults (May 2022). An sNDA for atopic dermatitis in adults and children two years and older is under FDA review, with a PDUFA action expected in the fourth quarter of calendar 2024.

04—Continue

← View all 8-K filings